Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMSZLJR)

Drug Name

Avelumab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Merkel cell carcinoma	2C34	Approved	[1]
Solid tumour/cancer	2A00-2F9Z	Approved	[2]
Ovarian cancer	2C73	Phase 3	[2]
Renal cell carcinoma	2C90	Phase 3	[2]
Melanoma	2C30	Phase 2	[2]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Programmed cell death 1 ligand 1 (PD-L1)	TT8ZLTI	PD1L1_HUMAN	Not Available	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Merkel cell carcinoma

ICD Disease Classification

2C34

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Programmed cell death 1 ligand 1 (PD-L1)	DTT	CD274	4.38E-07	0.37	2.1

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57.